Source comparison
PT-141 Receptor Pharmacology: Clinical Comparison to PDE5 Inhibitors and Flibanserin
Primary Mechanism MC4R agonism in hypothalamus → oxytocin/dopamine release PDE5 inhibition → cGMP accumulation → smooth muscle relaxation 5-HT1A agonism / 5-HT2A antagonism → serotonin modulation PT-141 is the only centrally acting arousal initiator; others mo
This comparison does not assign a generated winner or score.
- Primary Mechanism
- MC4R agonism in hypothalamus → oxytocin/dopamine release
- PDE5 inhibition → cGMP accumulation → smooth muscle relaxation
- 5-HT1A agonism / 5-HT2A antagonism → serotonin modulation
- PT-141 is the only centrally acting arousal initiator; others modulate downstream pathways
- Site of Action
- CNS (hypothalamus, limbic system)
- Peripheral vasculature (corpus cavernosum, clitoral tissue)
- CNS (prefrontal cortex, raphe nuclei)
- Central vs peripheral determines who responds
- Onset of Effect
- 45–60 minutes
- 30–60 minutes
- 4–8 weeks (chronic daily dosing required)
- PT-141 and PDE5 inhibitors are on-demand; flibanserin requires daily use
- Duration of Action
- 6–8 hours (single dose)
- 4–6 hours (sildenafil); 24–36 hours (tadalafil)
- Continuous (while maintained on daily therapy)
- PT-141 duration matches sexual encounter window
- Efficacy in Vascular Dysfunction
- High (mechanism independent of endothelial NO signaling)
- Low to none (requires intact vascular response)
- Not applicable (not indicated for vascular ED)
- PT-141 works when blood flow is compromised
- Efficacy in SSRI-Induced Dysfunction
- Moderate to high (bypasses serotonergic suppression)
- Low (SSRI blunts arousal upstream of PDE5)
- Low (compounds serotonergic suppression)
- PT-141 targets arousal circuits downstream of SSRI interference
- Nausea Incidence
- 40% at 1.75mg dose (MC3R cross-reactivity)
- <5%
- 10–15%
- MC3R activation is dose-limiting for PT-141
- Regulatory Status
- FDA-approved for hypoactive sexual desire disorder in premenopausal women (2019)
- FDA-approved for erectile dysfunction (1998)
- FDA-approved for hypoactive sexual desire disorder in premenopausal women (2015)
- PT-141 is the newest entrant with distinct mechanism